Treatment of chronic heart failure with a very low dose of antibodies to C-fragment of type 1 angiotensin II receptor

Abstract

The open randomized placebo-controlled prospective study was conducted; we documented improvement of global contractility and diastolic function of left ventricle, clinical and psychological status in 60 patients with chronic heart failure receiving a very low dose of antibodies to C-end fragment to AT1 receptors of angiotensin II for 6 months (Cardosten). The drug was well-tolerated.

Keywords

• хроническая сердечная недостаточность
• кардостен
• систолическая функция левого желудочка
• диастолическая функция левого желудочка